Edition:
United States

Abiomed Inc (ABMD.O)

ABMD.O on Nasdaq

163.96USD
22 Sep 2017
Change (% chg)

$4.17 (+2.61%)
Prev Close
$159.79
Open
$160.01
Day's High
$164.60
Day's Low
$159.51
Volume
355,780
Avg. Vol
309,866
52-wk High
$164.60
52-wk Low
$95.14

Latest Key Developments (Source: Significant Developments)

Abiomed maintains fiscal year 2018 revenue guidance
Monday, 28 Aug 2017 05:15pm EDT 

Aug 28 (Reuters) - Abiomed Inc :Says ‍is maintaining its fiscal year 2018 revenue guidance of $560 million to $575 million - SEC filing​.Says is ‍maintaining its fiscal year 2018 guidance for GAAP operating margin in range of 22% to 24%​.FY2018 revenue view $573.8 million -- Thomson Reuters I/B/E/S.  Full Article

ABIOMED says CFO Michael Tomsicek resigns
Monday, 28 Aug 2017 04:00pm EDT 

Aug 28 (Reuters) - ABIOMED Inc :ABIOMED announces resignation of chief financial officer and welcomes back former chief financial officer as consultant.Says CFO Michael Tomsicek resigned.ABIOMED Inc - ‍Former CFO, Robert Bowen, will return from retirement to support organization as a consultant until a new CFO has been recruited​.ABIOMED-‍Ian Mcleod to perform functions of principal financial officer, principal accounting officer on interim basis until permanent cfo has been hired​.  Full Article

Abiomed Impella 2.5 and Impella 5.0 heart pumps receive regulatory approval from Japan Ministry of Health, Labor & Welfare
Tuesday, 27 Sep 2016 07:53am EDT 

Abiomed Inc : Abiomed Impella 2.5 and Impella 5.0 heart pumps receive regulatory approval from Japan Ministry of Health, Labor & Welfare . Co planning future discussions with PMDA relating to potential regulatory reviews of Impella CP and Impella RP later this fiscal year . Plans to start supporting patients in Japan during Q4 of FY '17 . Company will conduct a post-market surveillance on Impella usage .Says does not expect material revenue until FY'18.  Full Article

Abiomed reports Q1 gaap earnings per share of $0.29
Thursday, 28 Jul 2016 07:00am EDT 

Abiomed Inc : Is maintaining its fiscal year guidance for gaap operating margin in range of 18% to 20% . Fy2017 revenue view $439.5 million -- Thomson Reuters I/B/E/S . Abiomed announces q1 fy 2017 revenue of $103.0 million, up 40% over prior year . Q1 gaap earnings per share $0.29 . Q1 earnings per share view $0.23 -- Thomson Reuters I/B/E/S . Q1 revenue $103 million versus i/b/e/s view $97.2 million .Is increasing lower end of its fiscal year 2017 revenue guidance with new range of $435 million to $445 million.  Full Article

Abiomed reports Q1 GAAP earnings per share of $0.29
Thursday, 28 Jul 2016 07:00am EDT 

Abiomed Inc : Abiomed announces q1 fy 2017 revenue of $103.0 million, up 40% over prior year . Q1 gaap earnings per share $0.29 . Q1 revenue $103 million versus i/b/e/s view $97.2 million . Q1 earnings per share view $0.23 -- Thomson Reuters I/B/E/S . Abiomed inc says increasing lower end of its fiscal year 2017 revenue guidance with new range of $435 million to $445 million . Abiomed inc says maintaining its fiscal year guidance for gaap operating margin in range of 18% to 20% .Fy2017 revenue view $439.5 million -- Thomson Reuters I/B/E/S.  Full Article

Abiomed Inc gives FY 2017 revenue guidance
Tuesday, 3 May 2016 07:00am EDT 

Abiomed Inc:Gives FY 2017 guidance for total revenues to be in the range of $430 million to $445 million.  Full Article

Abiomed Inc gives Q3 2016 revenue guidance
Monday, 11 Jan 2016 04:00pm EST 

Abiomed Inc:Says reported preliminary unaudited Q3 2016 revenue of approximately $85.8 million.  Full Article

BRIEF-Abiomed receives FDA PMA approval for Impella RP for right heart failure

* Abiomed receives FDA PMA approval for Impella RP for right heart failure Source text for Eikon: Further company coverage: